Lafayette R, Kristensen J, Stone A, Floege J, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 2023 Aug 14:S0140-6736(23)01554-4. doi: 10.1016/S0140-6736(23)01554.
PMID: 37591292